Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.



New and Noteworthy
Education Initiative in Pulmonology

  • COPD — Case Study: Triple Therapy for a Newly Diagnosed Patient With Severe COPD – Case Study
  • Treatment with long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs] and long-acting beta-2 agonists [LABAs]) is the cornerstone of pharmacologic therapy in patients with chronic obstructive pulmonary disease (COPD) who have high symptom burdens. The decision to add an inhaled corticosteroid ... more >>
  • COPD — CHEST: ETHOS Sub-Analysis Confirms Triple Therapy Benefit – BreakingMED
  • In patients with moderate-to-severe COPD, adding an inhaled corticosteroid to dual and triple therapy reduced yearly decline in lung function compared to no steroid treatment in a sub-group analysis of data from the phase III ETHOS study, which was presented in a poster at CHEST 2020—the virtual meeting of ... more >>
    V. Abramson, MD
  • EGPA — Flipped CME: Zooming in on Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Real World Practice – Webcast
  • Eosinophilic granulomatosis with polyangiitis (EGPA) is a hypereosinophilic syndrome that affects the small-to-medium sized vessels. EGPA is characterized by asthma, allergies, and a wide range of extrapulmonary manifestations. A rare disease, EGPA can be difficult to recognize and diagnose. Corticosteroids, ... more >>
    P. Seo, MD
    M. Wechsler, MD, MMSc
  • EGPA — Flipped CME: Zooming in on Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Real World Practice – Webcast
  • After years of treatment for severe asthma, the patient in this case develops new and worrisome symptoms. Given a classic presentation of eosinophilic granulomatosis with polyangiitis (EGPA), the patient is readily diagnosed. However, management proves to be challenging. Listen as Dr. Michael Wechsler and Dr. ... more >>
    P. Seo, MD
    M. Wechsler, MD, MMSc
  • EGPA — Flipped CME: Zooming in on Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Real World Practice – Webcast
  • In this case study, a previously healthy, athletic man develops persistent respiratory symptoms and puzzling blood blisters on his lower extremities. A second challenge arises for this patient once treatment is underway, because he is unable to taper from corticosteroids despite experiencing serious adverse ... more >>
    P. Seo, MD
    M. Wechsler, MD, MMSc
  • COPD — Covid-19: Patients with COPD, Asthma Should Continue Taking ICS – BreakingMED
  • It has been questioned whether or not inhaled corticosteroid use during Covid-19 increases mortality risk. But what about patients with COPD or asthma who are currently using ICS? This article looks at an observational study assessing ICS use among individuals in this patient population who contracted Covid- ... more >>
    A. Brixey, MD
  • COPD — Case Study: Triple Therapy for a Patient With Moderate to Very Severe COPD – BreakingMED
  • The main goals of chronic obstructive pulmonary disease (COPD) treatment remain improving patient symptoms and decreasing acute exacerbation risk. Currently available therapeutic approaches within a comprehensive treatment strategy can help achieve these goals. Large randomized controlled trials have recently ... more >>
    F. Martinez, MD, MS
  • COPD — Short-Term, Low-Dose Morphine Improves Health, Breathlessness in Patients with Severe COPD – BreakingMED
  • In patients with COPD, managing severe and refractory breathlessness is an important treatment goal. This report assesses the efficacy of oral, low-dose morphine in reducing breathlessness and improving health status for this patient population.
    A. Brixey, MD
  • COPD — ATS: Poverty, Race Bigger Barriers to COPD Care Than Rural/Urban Divide – BreakingMED
  • Disparity in care is a major problem in many chronic diseases, and COPD is no exception. This report looks at those disparities in care between patients living in rural and urban areas. These findings will be reported at the ATS 2020 virtual meeting.
    A. Brixey, MD
  • COPD — ATS: Markers of Heart Risk May Predict COPD Exacerbations – BreakingMED
  • Secondary analyses of data from a trial that found no independent benefit for beta-blockers in reducing COPD exacerbations identified specific markers of cardiovascular health associated with exacerbation risk. These new analyses of BLOCK study findings, both presented at the ATS 2020 virtual meeting, may be ... more >>
    A. Brixey, MD
  • Pulmonology Mastery in COPD
  • Pulmonology Mastery in COPD is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in COPD. The curriculum includes ... more >>
    B. Make, MD
  • Clinical Context: COPD
  • Clinical Context: COPD is designed to provide up-to-date information on patient identification, symptoms, risk factors, and current and emerging treatments and best practices in the management of COPD. The curriculum includes case studies at the point of care and MedPage Today meeting coverage that will ... more >>
    B. Make, MD
  • Pulmonary Arterial Hypertension @Point of Care
  • Pulmonary arterial hypertension (PAH) is a rare disorder associated with significant morbidity and mortality. Three PAH treatment pathways or targets have been identified—the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway. In 1995 the FDA approved the first treatment specifically ... more >>
    R. Channick, MD
  • Nontuberculous Mycobacterial Lung Disease @Point of Care
  • Nontuberculous mycobacterial (NTM) lung disease, a condition of progressive lung damage caused by mycobacterial species other than those that cause tuberculosis or leprosy, is occurring with increasing frequency in the United States. Characterized by difficulties in diagnosis, non-FDA-approved treatment ... more >>
    N. Schluger, MD
  • Chronic Obstructive Pulmonary Disease @Point of Care
  • Chronic obstructive pulmonary disease (COPD) is highly prevalent in the United States. About 13 million people have a diagnosis of COPD, yet the disease remains underdiagnosed, with an estimated 21 million individuals affected. Cigarette smoking is the primary cause and, while smoking rates have dropped, they ... more >>
    B. Make, MD
  • Asthma @Point of Care
  • Asthma @Point of Care™ platform provides a comprehensive knowledge base of current and emerging diagnostic and management strategies based on the most up-to-date scientific data and clinical trial results, guidance, and insights from top clinician specialists all delivered in ways to efficiently and ... more >>
    M. Wechsler, MD, MMSc
  • Cystic Fibrosis @Point of Care
  • Major advancements, including newborn screening, new treatments targeting the underlying cause of disease, and quality improvement initiatives, have transformed the continuum of care and survival outcomes for individuals with cystic fibrosis. The Cystic Fibrosis @Point of Care Edition provides a comprehensive ... more >>
    S. McColley, MD
  • Non-Small Cell Lung Cancer @Point of Care
  • Advances in our understanding of non-small-cell lung cancer (NSCLC) are leading to new strategies for diagnosis, staging, and treatment. This point-of-care clinical resource can help you stay informed about disease pathogenesis, molecular targets, and current and emerging management strategies based on the ... more >>
    M. Socinski, MD
  • COPD — Case Study: Triple Therapy for a Newly Diagnosed Patient With Severe COPD – Case Study
  • Treatment with long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs] and long-acting beta-2 agonists [LABAs]) is the cornerstone of pharmacologic therapy in patients with chronic obstructive pulmonary disease (COPD) who have high symptom burdens. The decision to add an inhaled corticosteroid ... more >>
  • COPD — Case Study: Triple Therapy for a Patient With Moderate to Very Severe COPD – BreakingMED
  • The main goals of chronic obstructive pulmonary disease (COPD) treatment remain improving patient symptoms and decreasing acute exacerbation risk. Currently available therapeutic approaches within a comprehensive treatment strategy can help achieve these goals. Large randomized controlled trials have recently ... more >>
    F. Martinez, MD, MS
  • Cystic Fibrosis — Lumacaftor/Ivacaftor Combo Improves BMI/QoL in Cystic Fibrosis Patients with Normal Lung Function – BreakingMED
  • Lumacaftor/ivacaftor continues to show benefit for the treatment of cystic fibrosis. This report looks at nutritional status, sweat chloride levels, and exacerbation rates among cystic fibrosis patients with normal lung function at baseline.
    A. Brixey, MD
  • COPD — Antibiotics, Steroids Reduce Tx Failure for Patients with COPD Exacerbations – BreakingMED
  • Managing COPD exacerbations is clinically challenging, but a systematic review and meta-analysis suggests that use of antibiotics and corticosteroids appears to reduce treatment failure. Nonetheless, researchers were unable to identify an optimum antibiotic/corticosteroid combination.
    A. Brixey, MD
  • COPD — CHEST 2019: Putting it in Practice – Webcast
  • CHEST 2019 showcased the latest COPD research findings including results from real-world studies. In this exclusive video Barry J. Make, MD, Co-Director of the COPD Program, Division of Pulmonary and Critical Care Medicine, National Jewish Health, in Denver reviews those findings and explains how they can be ... more >>
    B. Make, MD
  • Cystic Fibrosis — Lumacaftor/Ivacaftor Combo Improves Lung Function in Real-World CF Trial – BreakingMED
  • The combination therapy lumacaftor/ivacaftor was approved in 2015. In this report, researchers look at its real-world efficacy for CF patients—specifically, whether the rate of spirometric indices decline improved after the initiation of lumacaftor/ivacaftor administration in homozygous F508del CF patients, ... more >>
    A. Brixey, MD
  • COPD — Nebulized LAMA May Have Advantage Over Dry Powder for Some COPD Patients – BreakingMED
  • Deciding whether to use a nebulized long-acting muscarinic antagonist versus a dry powder LAMA can be difficult for patients with COPD. This article discusses how that choice often depends on patients’ sub-optimal peak inspiratory flow rate (sPIFR).
    A. Brixey, MD
  • Cystic Fibrosis — Worsening Sinus Symptoms Linked to Pulmonary Declines in Cystic Fibrosis – BreakingMED
  • Understanding triggers for pulmonary exacerbations is key to management of cystic fibrosis. In this report, researchers suggest a temporal link between rhinosinusitis symptoms and pulmonary exacerbations and note the importance of SNOT-22 test and CF quality of life questionnaire.
    A. Brixey, MD
  • Asthma — Ask the Experts: Treatment Options for Asthma—All Severities Considered – Webcast
  • Asthma is a heterogeneous disease with multiple underlying mechanisms that produce common clinical symptoms, which can make the diagnosis and treatment of this disease difficult. Asthma can be categorized based on clinical characteristics and phenotypes, and recent years have seen the development of several ... more >>
    D. Ledford, MD
    W. Soong, MD
  • COPD — COPD Intervention Ineffective – BreakingMED
  • In an unexpected twist, a single-site randomized clinical trial found that a program designed to provide transitional care and long-term self-management support to patients hospitalized with chronic obstructive pulmonary disease (COPD) was largely ineffective, according to researchers from Johns Hopkins ... more >>
    A. Brixey, MD
  • COPD — Case Study: Triple Therapy for a Newly Diagnosed Patient With Severe COPD – Case Study
  • Treatment with long-acting bronchodilators (long-acting muscarinic antagonists [LAMAs] and long-acting beta-2 agonists [LABAs]) is the cornerstone of pharmacologic therapy in patients with chronic obstructive pulmonary disease (COPD) who have high symptom burdens. The decision to add an inhaled corticosteroid ... more >>
  • Asthma — Case Study: Investigational Single-Inhaler Triple Therapy for Uncontrolled Asthma – Case Study
  • Asthma is a heterogeneous disease in which treatment with inhaled corticosteroids (ICS), with or without a long-acting beta-2 agonist (LABA) bronchodilator, is highly effective. Yet, up to 40% of patients remain uncontrolled after stepwise increases in therapy. Even with the availability of add-on biologics ... more >>
    W. Soong, MD
  • Asthma — Case Study: Management of a Patient With Severe Eosinophilic Asthma – Case Study
  • Severe asthma may remain uncontrolled with inhaled corticosteroids and a long-acting bronchodilator, despite optimal treatment and good adherence, and management often requires use of periodic or maintenance oral corticosteroids. Type 2 inflammation, characterized by the presence of interleukin (IL)-4, IL-5, ... more >>
    J. Corren, MD
  • Asthma — Case Study: Biologic Therapy for Allergic Asthma – Case Study
  • For patients with severe allergic asthma who are not adequately controlled with inhaler therapy, it may be necessary to consider the addition of biologic therapy. Choosing among the available biologic therapies involves taking into account the patient's asthma endotype based on biomarkers such as eosinophil ... more >>
    E. DiMango, MD
  • COPD — Case Study: Managing a Patient With Mild, Worsening COPD, Including Proper Use of Inhaler – Case Study
  • This case study in the Pulmonology Mastery in COPD program follows a 50-year-old smoker diagnosed with mild chronic obstructive pulmonary disease (COPD) who is now experiencing increasing shortness of breath. She has not been using her short-acting bronchodilator inhaler correctly, and it has been ... more >>
    B. Make, MD
  • COPD — Case Study: Managing Mild to Moderate COPD in a Patient With Exacerbations – Case Study
  • Acute exacerbations of chronic obstructive pulmonary disease (COPD) can occur even in patients with mild to moderate obstruction to airflow. For this reason, it is imperative to ensure these patients receive effective treatment as early as possible in the disease. This case illustrates the real-life scenario ... more >>
    B. Make, MD
  • COPD — Case Study: Smoker With Severe COPD – Case Study
  • This case study in the Pulmonology Mastery in Chronic Obstructive Pulmonary Disease (COPD) program follows the progression of a 55-year-old former smoker. Currently, her COPD is poorly controlled on a long-acting muscarinic antagonist/long-acting beta-2 agonist combination treatment. Her current diagnosis and ... more >>
    B. Make, MD
  • COPD — Management of a Moderate COPD Patient – Case Study
  • This activity reviews a real-life case scenario of a female patient with undiagnosed chronic obstructive pulmonary disease (COPD) visiting her primary care physician. The case demonstrates approaches to the assessment, diagnosis, and treatment of COPD, and also stresses the importance of counseling patients ... more >>
    B. Make, MD
  • COPD — Case Study: Severe COPD Patient With Shortness of Breath – Case Study
  • This case study in the Pulmonary Mastery in COPD series examines a 51-year-old woman with chronic obstructive pulmonary disease (COPD) who presents with a 1-year history of dyspnea on exertion. She is currently experiencing shortness of breath on a long-acting beta 2 agonist/inhaled corticosteroid combination ... more >>
    B. Make, MD
  • COPD — Treatment of a Patient With Newly Diagnosed COPD – Case Study
  • Choosing appropriate initial therapy for patients with newly diagnosed chronic obstructive pulmonary disease (COPD) can be challenging. However, consensus recommendations based on best available evidence offer guidance on the choice of therapy. This case illustrates the real-life case scenario of a patient ... more >>
    B. Make, MD

    We appreciate our customers and hold ourselves to the highest privacy standards.

    Access My Information or Delete My Information